我院替格瑞洛相关不良反应的分析Analysis of Adverse Drug Reactions Induced by Ticagrelor in Our Hospital
林东兰,罗利琼,陈健达,邝植雄
LIN Donglan,LUO Liqiong,CHEN Jianda,KUANG Zhixiong
摘要(Abstract)：
目的监测替格瑞洛的不良反应,为其安全用药提高参考。方法对2020年4～9月在我院首次服用替格瑞洛的195例患者进行为期1年的随访,分析其服药后的ADR情况。结果 195例患者中有23例(11.79%)发生27例替格瑞洛相关的药物不良反应(ADR),发生时间最快为首次服药后2 h,最迟为36 w,绝大多数(18例,66.67%)发生在2 w内,症状多为轻、中度;主要累及器官/系统为呼吸系统(59.26%);主要临床表现为呼吸困难12例(44.44%)和轻微出血10例(37.04%);1例呼吸困难可能与ARB能增加替格瑞洛相关呼吸困难风险有关;1例血透患者使用替格瑞洛无不适症状。结论替格瑞洛安全性高,较少严重的不良反应,但由于其在我国上市晚,在药物相互作用及特殊人群用药方面缺少循证医学证据。药师应加强临床用药监测,重视药物相互作用,减少药物不良反应,确保临床用药安全。
OBJECTIVE To monitor adverse drug reactions(ADR) induced by ticagrelor, and provide reference for safe drug use. METHODS 195 patients received ticagrelor firstly in our hospital from April 2020 to September 2020 were followed-up for 1 year, and the ADR situation was analyzed and summarized after taking drug. RESULTS In the 195 patients, 23 patients(11.79%) suffered from 27 cases of ticagrelor-related ADR.The earliest occurrence time was 2 hours after the first administration, and the latest was 36 weeks later.The vast majority(18 cases, 66.67%) occurred within 2 weeks.And the symptoms were mostly mild or moderate.The mainly involved organ/system was respiratory system(59.26%).The main clinical manifestations were dyspnea(44.44%) and eminor bleeding(37.04%).One case of dyspnea might be related to ARB,which was an added risk for developing dyspnea on ticagrelor.One patient of hemodialysis had no discomfort after taking drug. CONCLUSION Ticagrelor has good safety and little serious ADR.But due to its shorter time to market in China and lack of evidence-based medicine in drug interactions and drug use for special population, pharmacists should strengthen clinical medication monitoring and pay attention to drug interactions to reduce the ADR and ensure clinical medication safety.
关键词(KeyWords)：
替格瑞洛;不良反应;分析;基层医院
ticagrelor;adverse drug reaction;analysis;the basic level hospital
基金项目(Foundation): 江门市卫生计生局科研立项项目(江卫函[2020]256号-20A135)
作者(Author):
林东兰,罗利琼,陈健达,邝植雄
LIN Donglan,LUO Liqiong,CHEN Jianda,KUANG Zhixiong
参考文献(References)：
- [1] Wallentin L,Becker R C,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
- [2] 谢立，张文颖.我院替格瑞洛致不良反应108例分析[J].中国药房，2016,27(29):4085-4087.
- [3] 孙秀波，付春毅，张亚同，等.新型抗血小板聚集药物：替格瑞洛的研究进展[J].中国药房，2015,26(14):2010-2013.
- [4] 李海玲，侯攀，郭显，等.急性冠状动脉综合征患者替格瑞洛相关呼吸困难的危险因素分析[J].第二军医大学学报，2020,41(1):11-17.
- [5] 王栋，崔晓冉，李汭傧，等.不同剂量的替格瑞洛治疗不稳定型心绞痛的疗效和安全性比较[J].临床心血管病杂志，2020,36(6):549-553.
- [6] 张燕，尚珊珊，郭俊.替格瑞洛治疗非ST段抬高型急性冠脉综合征合并慢性阻塞性肺疾病患者的效果[J].中华老年多器官疾病杂志，2019,18(12):913-917.
- [7] Wittfeldt A,Emanuelsson H,Brandrup-Wognsen G,et al.Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans[J].J Am Coll Cardiol,2013,61(7):723-727.
- [8] 边桂芝，钟燕，田雅兰，等.替格瑞洛上市后呼吸系统不良反应信号检测与分析[J].中国新药杂志，2016,25(20):2390-2394.
- [9] Goodman S G,Clare R,Pieper K S,et al.Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor[J].Circulation,2012,125(8):978-986.
- [10] Teng R,Mitchell P D,Butler K A.Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers[J].Eur J Clin Pharmacol,2013,69(3):477-487.
- [11] Dinicolantonio J J,Serebruany V L.Exploring the ticagrelor-statin interplay in the PLATO trial[J].Cardiology,2013,124(2):105-107.
- [12] BrilintaTM(ticagrelor) Tablets:A P2Y(12) platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS)[J].P T,2012,37(4 section 2):4-18.
- [13] DiNicolantonio J J,Serebruany V L.Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor:A potential ticagrelor-angiotensin receptor blocker interaction?[J].Clin Cardiol,2012,35(11):647-648.
- [14] Bonaca M P,Bhatt D L,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med,2015,372(19):1791-1800.
- [15] 杨昭毅，向倩，周颖，等.新型抗血小板药物替格瑞洛临床应用分析[J].中国新药杂志，2015,24(2):235-240.